Mona Ashiya Sells 5,738 Shares of Disc Medicine, Inc. (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) Director Mona Ashiya sold 5,738 shares of Disc Medicine stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $54.11, for a total value of $310,483.18. Following the sale, the director now directly owns 186,541 shares in the company, valued at $10,093,733.51. The trade was a 2.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Mona Ashiya also recently made the following trade(s):

• On Friday, March 21st, Mona Ashiya sold 10,011 shares of Disc Medicine stock. The shares were sold at an average price of $54.00, for a total transaction of $540,594.00.
• On Wednesday, March 19th, Mona Ashiya sold 39,656 shares of Disc Medicine stock. The shares were sold at an average price of $54.02, for a total transaction of $2,142,217.12.
• On Wednesday, March 12th, Mona Ashiya sold 83,182 shares of Disc Medicine stock. The shares were sold at an average price of $54.45, for a total value of $4,529,259.90.
• On Monday, March 10th, Mona Ashiya sold 202,146 shares of Disc Medicine stock. The shares were sold at an average price of $54.29, for a total transaction of $10,974,506.34.

Disc Medicine Price Performance

IRON stock traded down $0.11 during midday trading on Friday, hitting $52.36. The company's stock had a trading volume of 427,241 shares, compared to its average volume of 364,105. The company's fifty day moving average price is $54.64 and its 200 day moving average price is $56.20. Disc Medicine, Inc. has a twelve month low of $25.60 and a twelve month high of $68.73. The stock has a market capitalization of $1.81 billion, a P/E ratio of -13.16 and a beta of 0.73.

Remove Ads

Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $0.08. Equities analysts expect that Disc Medicine, Inc. will post -4.07 EPS for the current fiscal year.

Institutional Trading of Disc Medicine

Several institutional investors and hedge funds have recently bought and sold shares of the business. GF Fund Management CO. LTD. acquired a new position in shares of Disc Medicine in the fourth quarter valued at $40,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Disc Medicine by 399.2% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 93,103 shares of the company's stock worth $5,903,000 after buying an additional 74,454 shares during the period. Woodline Partners LP lifted its holdings in shares of Disc Medicine by 5.2% during the fourth quarter. Woodline Partners LP now owns 396,600 shares of the company's stock worth $25,144,000 after buying an additional 19,538 shares in the last quarter. ProShare Advisors LLC boosted its position in shares of Disc Medicine by 26.5% in the fourth quarter. ProShare Advisors LLC now owns 6,966 shares of the company's stock valued at $442,000 after acquiring an additional 1,458 shares during the period. Finally, MPM Bioimpact LLC grew its stake in shares of Disc Medicine by 11.1% in the fourth quarter. MPM Bioimpact LLC now owns 346,401 shares of the company's stock valued at $21,962,000 after acquiring an additional 34,640 shares in the last quarter. Institutional investors own 83.70% of the company's stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Scotiabank raised their price objective on shares of Disc Medicine from $73.00 to $75.00 and gave the stock a "sector outperform" rating in a report on Monday, March 3rd. Stifel Nicolaus upped their target price on shares of Disc Medicine from $90.00 to $94.00 and gave the stock a "buy" rating in a research report on Friday, January 24th. Cantor Fitzgerald boosted their price objective on shares of Disc Medicine from $99.00 to $132.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 18th. Morgan Stanley reaffirmed an "overweight" rating and issued a $85.00 target price on shares of Disc Medicine in a research note on Friday, March 7th. Finally, HC Wainwright reiterated a "buy" rating and issued a $118.00 price target on shares of Disc Medicine in a research report on Tuesday, January 21st. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $93.80.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.